Insilico Medicine S Ai Zeroes In On New Drug Targets For Aging Age Using aging as a way to identify disease, he says, insilico has trained ai to do what it does best — take large amounts of data from many components to identify new targets, and new molecules. New research published tuesday in the journal aging describes how insilico’s pandaomics software was able to predict molecular targets for new drugs to treat both aging and.
Insilico Medicine Ushers In A New Era Of Ai Led Drug Design New research published tuesday in the journal aging describes how insilico’s pandaomics software was able to predict molecular targets for new drugs to treat both aging and age associated diseases like alzheimer’s, parkinson’s, cirrhosis, rheumatoid arthritis and more. You can look at yourself in the mirror or in the passport. but there are very, very few ways to intervene in aging," zhavoronkov explained. his hypothesis drives insilico's research: if a drug is powerful enough to target aging mechanisms, it should be effective against multiple diseases. Insilico medicine has announced a new wave of cardiometabolic programs discovered through its proprietary generative ai platform, pharma.ai, positioning metabolic optimization as a cornerstone of longevity focused medicine. The new ai powered model training framework for therapeutic target discovery was unveiled in a paper published on biorxiv, introducing targetpro and targetbench 1.0 as complementary systems designed to accelerate and validate the earliest and most critical stage of drug development.
Insilico Ceo Discusses Ai Driven Drug Discovery Insilico medicine has announced a new wave of cardiometabolic programs discovered through its proprietary generative ai platform, pharma.ai, positioning metabolic optimization as a cornerstone of longevity focused medicine. The new ai powered model training framework for therapeutic target discovery was unveiled in a paper published on biorxiv, introducing targetpro and targetbench 1.0 as complementary systems designed to accelerate and validate the earliest and most critical stage of drug development. Insilico medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (cns), and aging related diseases. On november 7, 2025 at bio europe, insilico medicine disclosed eight oral small molecule programs for cardiometabolic diseases discovered with its pharma.ai platform. Now, a study conducted by feng ren and colleagues leverages a multistage generative artificial intelligence (ai) platform to identify and validate a small molecule tnik inhibitor to target. By tailoring predictive ai models to individual diseases and creating the first standardized benchmarking system for evaluating target discovery platforms, insilico is establishing a new gold standard of accuracy and transparency in the field.
Insilico Medicine Achieves Ai Drug Discovery Breakthrough Insilico medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (cns), and aging related diseases. On november 7, 2025 at bio europe, insilico medicine disclosed eight oral small molecule programs for cardiometabolic diseases discovered with its pharma.ai platform. Now, a study conducted by feng ren and colleagues leverages a multistage generative artificial intelligence (ai) platform to identify and validate a small molecule tnik inhibitor to target. By tailoring predictive ai models to individual diseases and creating the first standardized benchmarking system for evaluating target discovery platforms, insilico is establishing a new gold standard of accuracy and transparency in the field.
Comments are closed.